We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information for healthcare professionals, patients, and the public.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
Information for patients, public and health care professionals.
Projects granted during 2014 that have a primary purpose of basic research: oncology.
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
Information on the programme, including commissioning, quality assurance, education and training.
You may need to tell DVLA if you have cancer - if you do, download the correct form to let them know
This study aims to identify the clinical and histopathologic predictors of lymph node metastasis among patients with oral SCC
You may need to tell DVLA if you have lung cancer - download the correct form if you need to let them know
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Projects granted during 2016 that have a primary purpose of basic research, oncology.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.